Our pipeline
im体育首页有一个令人兴奋和平衡的管道，由伟大的科学支撑.
Latest quarterly updates
im体育首页的产品线在临床开发的不同阶段形成了强大的研究性疗法组合.
179
projects in our pipeline
15
new molecular entities in our late-stage pipeline
1
new molecular entity approved
III期/LCM项目:指II/III期的关键资产, 或者已经提交监管审批的, 可能包括现在在一个或多个主要市场推出的资产(在所有适用的主要市场推出时删除).
Filter By:
Oncology (as of 9 February 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
心血管、肾脏及新陈代谢(截至2023年2月9日)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Respiratory & Immunology (as of 9 February 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Rare Disease (as of 9 February 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
Vaccine & Immune therapies (as of 9 February 2023)
Phase I
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects
LCM Projects
Other (as of 9 February 2023)
Phase I
Phase II
Phase II
Phase III
Phase III
LCM Projects